Psychiatr. pro Praxi, 2003; 5: 201-204

Novinky ve zvyšování hmotnosti a v metabolických komplikacích po antipsychotikách

prof. MUDr. Štěpán Svačina DrSc
III. interní klinika VFN a 1. LF UK, Praha

Keywords: hyperlipoproteinemia, diabetes, schizophrenia, depression, education of patients.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svačina Š. Novinky ve zvyšování hmotnosti a v metabolických komplikacích po antipsychotikách. Psychiatr. praxi. 2003;4(5):201-204.

Nová antipsychotika přinášejí zásadní změnu kvality v psychiatrické léčbě. Bohužel častým vedlejším účinkem je vzestup hmotnosti, vznik diabetu a vzestup hladiny lipidů. V poslední době se zdá, že rozdíly mezi jednotlivými antipsychotiky ve výskytu těchto vedlejších účinků jsou menší než se dříve myslelo. Celosvětově je totiž více využívána edukace pacientů a tím se stávají rizika jednotlivých skupin léků srovnatelná. O nutnosti dietních a režimových opatření k prevenci metabolických komplikací by měl být poučen každý pacient.

New information on weight gain and metabolic complications during treatment with psychotherapeutics

New antipsychotic drugs have resulted in principal change in quality of psychiatric care. Unfortunately, weight gain, development of diabetes and rise in serum lipid levels are the frequent side effects. It seems lately, that differences in occurrence of these side effects among particular psychotherapeutics are minor than previously assumed. All over the world, attention is being given to education of patients and thus risks of particular groups of drugs have become comparable. Each patient should be advised of necessity of dietary and regime arrangements to prevent metabolic complications.

Download citation

References

  1. Atmaca M, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003; 64: 598-604. Go to original source... Go to PubMed...
  2. Baptista T, et al. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35: 205-219. Go to original source... Go to PubMed...
  3. Buse JB, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epid. 2003; 56: 164-170. Go to original source... Go to PubMed...
  4. Henderson DC. Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents. Curr Diab Rep. 2002; 2: 135-140. Go to original source... Go to PubMed...
  5. Mc Intyre RS, et al. Antipsychotic metabolic effect Weight gain, diabetes mellitus and Lipid abnotrmalities. Can. J. Psychiatry 2001; 46: 273-281. Go to original source... Go to PubMed...
  6. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002; 63: 425-433. Go to original source... Go to PubMed...
  7. Papakostas GI, et al. Serum cholesterol in treatment-resistant depression. Neuropsychobiology. 2003; 47: 146-151. Go to original source... Go to PubMed...
  8. Peters H, et al. Serum cholesterol level comparison: control subjects, anxiety disorder patients, and obsessive-compulsive disorder patients. Can J Psychiatry. 2002; 47: 557-562. Go to original source... Go to PubMed...
  9. Sonawalla SB, et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder.: Psychosomatics. 2002; 43: 310-316. Go to original source... Go to PubMed...
  10. Svačina Š. Obezita a psychofarmaka. Triton 2002.
  11. Svačina Š, Owen K. Syndrom inzulínové rezistence. Triton 2003.
  12. Svačina Š. Prevence diabetu. Galén 2003.
  13. Svačina Š. Lipidy a psychofarmaka Ateroskleróza - metabolismus - klinika - liečba, 7, 2003, v tisku.
  14. Šmahelová A. Akutní hyperglykemické komplikace u diabetu 1. a 2. typu. Trendy v diabetologii 5. Galen 2001.
  15. Wetterling T. Hyperlipidemia-side-effect of the treatment with an atypical antipsychotic (zotepine) Psychiatr Prax. 2002; 29: 438-440. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.